Several groups studied the use of a variant of measles virus encoding CEA for the treatment of prostate [81], glioblastoma [82], and ovarian [83] cancer and demonstrated delayed tumour progression and increased survival in mouse models. This evidence concerns the gene CEACAM5 and neoplasm.